Abatacept in the treatment of rheumatoid arthritis

References

• BuchMBoyleDSaleemBThe selective co-stimulation modulator abatacept decreases synovial inflammation and expression of pro-inflammatory cytokines in patients with rheumatoid arthritisArthritis Rheum200552SupplS446
   Google Scholar
• DavisPMNadlerSGSuchardSJAbatacept differentially modulates human B-cell and dendritic cell stimulated T-cell effector functionAnn Rheum Dis200564Suppl III128
   Google Scholar
• DavidsonADiamondBWofsyDBlock and tackle: CTLA4Ig takes on lupusLupus20051419720315807196
   PubMed Web of Science ®Google Scholar
• DougadosMSherrerYCarrabbaMAbatacept provides significant and clinically meaningful efficacy in rheumatoid arthritis patients with inadequate responses to anti-TNF therapy: disease activity score 28 assessments in the ATTAIN trialAnn Rheum Dis200564Suppl III458
   Google Scholar
• EhrensteinMREvansJGSinghACompromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapyJ Exp Med20042002778515280421
   PubMed Web of Science ®Google Scholar
• EmeryPCombeBNuamahIPatients with rheumatoid arthritis treated with abatacept (CTLA4Ig; BMS-188667) report rapid improvements in pain, disease activity and physical functionAnn Rheum Dis200463Suppl I52515082482
   PubMedGoogle Scholar
• EmeryPRussellATateGAbatacept induces sustained improvements in health-related quality of life, sleep quality and fatigue over 3 years in rheumatoid arthritis patients with inadequate methotrexate responsesAnn Rheum Dis200564Suppl III40315297281
   PubMedGoogle Scholar
• EmeryPWesthovensRLeonGBenficial effects of the selective co-stimulation modulator abatacept on biomarkers of rheumatoid arthritis immunopathology in patients with an inadequate response to methotrexate or TNF-inhibitor treatmentAnn Rheum Dis200564Suppl III432
   Google Scholar
• GenantHPeterfyCPairaSAbatacept significantly inhibits structural damage progression as assessed by the genant-modified sharp scoring system in rheumatoid arthritis patients with inadequate response to methotrexateAnn Rheum Dis200564Suppl III5615608301
   PubMedGoogle Scholar
• GenoveseMSchiffMLuggenMEfficacy of Abatacept following wash-out of anti-TNF therapy in rheumatoid arthritis patients in the ATTAIN (Abatacept Trial in Treatment of Anti-TNF Inadequate Responders) Trial: current versus prior discontinuationArthritis Rheum200552S5601
   Google Scholar
• GenoveseMCBeckerJCSchiffMAbatacept for Rheumatoid Arthritis refractory to tumour necrosis factor a inhibitionN Engl J Med200535311142316162882
   PubMed Web of Science ®Google Scholar
• GoughSCLWalkerLSKSansomDMCTLA4 gene polymorphism and autoimmunityImmunol Rev20052041021515790353
   PubMed Web of Science ®Google Scholar
• JenkinsMKTaylorPSNortonSDCD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cellsJ Immunol1991147246161717561
   PubMed Web of Science ®Google Scholar
• KremerJMWesthovensRLeonMTreatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4IgN Engl J Med200334919071514614165
   PubMed Web of Science ®Google Scholar
• KremerJMWesthovensRAbud-MendozaCAbatacept improves American College of Rheumatology responses and disease activity score 28 remission rates in both recent-onset and more established rheumatoid arthritis: results from the AIM trialArthritis Rheum200552S5623
   Google Scholar
• KremerJShergyWTindallESustained clinical efficacy demonstrated by the selective co-stimulation modulator abatacept (CTLA4Ig) in combination with methotrexate at 2 years in rheumatoid arthritis patients with an inadequate response to methotrexateArthritis Rheum200450S182
   Google Scholar
• KremerJMDougadosMEmeryPTreatment of rheumatoid arthritis with the selective costimulation modulator abatacept – twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trialArthritis Rheum20055222637116052582
   PubMed Web of Science ®Google Scholar
• LinsleyPSBradyWUrnesMCTLA-4 is a second receptor for the B cell activation antigen B7J Exp Med199117456191714933
   PubMed Web of Science ®Google Scholar
• MimaTSaekiYOhshimaSTransfer of rheumatoid arthritis into severe combined immunodeficient mice. The pathogenetic implications of T cell populations oligoclonally expanding in the rheumatoid jointsJ Clin Invest1995961746587560066
   PubMed Web of Science ®Google Scholar
• MorelandLWAltenRVan den BoschFCostimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusionArthritis Rheum2002461470912115176
   PubMed Web of Science ®Google Scholar
• MorelandLUnmet needs in rheumatoid arthritisArthritis Res Ther20057Suppl 3S2815960819
   PubMed Web of Science ®Google Scholar
• NadlerSTownsendRMikesellGAbatacept (CTLA4-IG; BMS-188667) significantly inhibits T-cell proliferation in vitro at clinically relevant concentrationsAnn Rheum Dis200463suppl142
   Google Scholar
• NdejembiMPPatkeDSBingamanAWCTLA4-Ig treatment promotes loss of antigen-activated effector memory CD4 T-cellsArthritis Rheum200552SupplS4923
   Google Scholar
• PonchelFMorganAWBinghamSJDysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritisBlood20021004550612393721
   PubMed Web of Science ®Google Scholar
• RussellAEmeryPKafkaSPAbatacept improves clinical responses regardless of baseline physical function: results from the AIM trialArthritis Rheum200552S543
   Google Scholar
• SakaguchiNTakahashiTHataHAltered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in miceNature20034264546014647385
   PubMed Web of Science ®Google Scholar
• Salazar-FontanaLISanzEMe´ridaCell surface CD28 levels define four CD41 T cell subsets: abnormal expression in rheumatoid arthritisClin Imm20019925365
   PubMed Web of Science ®Google Scholar
• SchiffMDougadosMLuggenMAbatacept leads to significant improvements in all American college of rheumatology core components in patients with an inadequate response to anti-TNF therapy in the ATTAIN trialAnn Rheum Dis200564Suppl III435
   Google Scholar
• SymingtonFWBradyWLinsleyPSExpression and function of B7 on human epidermal langerhans cellsJ Immunol19931501286957679425
   PubMed Web of Science ®Google Scholar
• TalamoJFraterAGallivanSUse of the short form 36 (SF36) for health status measurement in rheumatoid arthritisBr J Rheumatol19973646399159541
   PubMedGoogle Scholar
• TangQBodenEKHenriksenKJdistinct roles of CTLA-4 and TGF-b in CD4+CD25+ regulatory T cell functionEur J Imm20043429963005
   PubMed Web of Science ®Google Scholar
• TownsendRMKliwinskiCKukralDProphylactic administration of abatacept prevents disease induction and bone destruction in a rat model of collagen-induced arthritisAnn Rheum Dis200564Suppl III439
   Google Scholar
• VincentiFLarsenCDurrbachACostimulation blockade with belatacept in renal transplantationN Engl J Med20053537708116120857
   PubMed Web of Science ®Google Scholar
• WeinblattMCombeBWhiteASafety of abatacept in patients with active rheumatoid arthritis receiving background non-biologi and biologic DMARDs: 1 year results of the ASSURE trialAnn Rheum Dis200564Suppl III60
   Google Scholar
• WeismanMDurezPHalleguaDAbatacept (CTLA4; BMS-188667) inhibits T-cell activation and the subsequent activation of inflammatory cell types, as demonstrated by sustained reductions in multiple inflammatory biomarkersAnn Rheum Dis200463Suppl I13814722201
   PubMedGoogle Scholar